Sökning: WFRF:(Quiros Jose Ramon) > Differences in the ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06824naa a2200913 4500 | |
001 | oai:DiVA.org:umu-100162 | |
003 | SwePub | |
008 | 150224s2014 | |||||||||||000 ||eng| | |
009 | oai:lup.lub.lu.se:52bd9e1a-b683-4679-8363-e90894aeece0 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1001622 URI |
024 | 7 | a https://doi.org/10.1016/S2213-8587(14)70146-92 DOI |
024 | 7 | a https://lup.lub.lu.se/record/46151542 URI |
040 | a (SwePub)umud (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Forouhi, Nita G.4 aut |
245 | 1 0 | a Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes :b the EPIC-InterAct case-cohort study |
264 | 1 | c 2014 |
338 | a electronic2 rdacarrier | |
520 | a Background Conflicting evidence exists regarding the association between saturated fatty acids (SFAs) and type 2 diabetes. In this longitudinal case-cohort study, we aimed to investigate the prospective associations between objectively measured individual plasma phospholipid SFAs and incident type 2 diabetes in EPIC-InterAct participants. Methods The EPIC-InterAct case-cohort study includes 12 403 people with incident type 2 diabetes and a representative subcohort of 16 154 individuals who were selected from a cohort of 340 234 European participants with 3 . 99 million person-years of follow-up (the EPIC study). Incident type 2 diabetes was ascertained until Dec 31, 2007, by a review of several sources of evidence. Gas chromatography was used to measure the distribution of fatty acids in plasma phospholipids (mol%); samples from people with type 2 diabetes and subcohort participants were processed in a random order by centre, and laboratory staff were masked to participant characteristics. We estimated country-specific hazard ratios (HRs) for associations per SD of each SFA with incident type 2 diabetes using Prentice-weighted Cox regression, which is weighted for case-cohort sampling, and pooled our findings using random-effects meta-analysis. Findings SFAs accounted for 46% of total plasma phospholipid fatty acids. In adjusted analyses, different individual SFAs were associated with incident type 2 diabetes in opposing directions. Even-chain SFAs that were measured (14: 0 [myristic acid], 16: 0 [palmitic acid], and 18: 0 [stearic acid]) were positively associated with incident type 2 diabetes (HR [95% CI] per SD difference: myristic acid 1.15 [95% CI 1.09-1.22], palmitic acid 1.26 [1.15-1.37], and stearic acid 1.06 [1.00-1.13]). By contrast, measured odd-chain SFAs (15: 0 [pentadecanoic acid] and 17: 0 [heptadecanoic acid]) were inversely associated with incident type 2 diabetes (HR [95% CI] per 1 SD difference: 0.79 [0.73-0.85] for pentadecanoic acid and 0.67 [0.63-0.71] for heptadecanoic acid), as were measured longer-chain SFAs (20: 0 [arachidic acid], 22:0 [behenic acid], 23:0 [tricosanoic acid], and 24:0 [lignoceric acid]), with HRs ranging from 0.72 to 0.81 (95% CIs ranging between 0.61 and 0.92). Our findings were robust to a range of sensitivity analyses. Interpretation Different individual plasma phospholipid SFAs were associated with incident type 2 diabetes in opposite directions, which suggests that SFAs are not homogeneous in their effects. Our findings emphasise the importance of the recognition of subtypes of these fatty acids. An improved understanding of differences in sources of individual SFAs from dietary intake versus endogenous metabolism is needed. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Endokrinologi och diabetes0 (SwePub)302052 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Endocrinology and Diabetes0 (SwePub)302052 hsv//eng |
700 | 1 | a Koulman, Albert4 aut |
700 | 1 | a Sharp, Stephen J.4 aut |
700 | 1 | a Imamura, Fumiaki4 aut |
700 | 1 | a Kroger, Janine4 aut |
700 | 1 | a Schulze, Matthias B.4 aut |
700 | 1 | a Crowe, Francesca L.4 aut |
700 | 1 | a Huerta, Jose Maria4 aut |
700 | 1 | a Guevara, Marcela4 aut |
700 | 1 | a Beulens, Joline W. J.4 aut |
700 | 1 | a van Woudenbergh, Geertruida J.4 aut |
700 | 1 | a Wang, Laura4 aut |
700 | 1 | a Summerhill, Keith4 aut |
700 | 1 | a Griffin, Julian L.4 aut |
700 | 1 | a Feskens, Edith J. M.4 aut |
700 | 1 | a Amiano, Pilar4 aut |
700 | 1 | a Boeing, Heiner4 aut |
700 | 1 | a Clavel-Chapelon, Francoise4 aut |
700 | 1 | a Dartois, Laureen4 aut |
700 | 1 | a Fagherazzi, Guy4 aut |
700 | 1 | a Franks, Paul W.u Lunds universitet,Umeå universitet,Medicin,Lund University, Malmö, Sweden,Genetisk och molekylär epidemiologi,Forskargrupper vid Lunds universitet,Genetic and Molecular Epidemiology,Lund University Research Groups4 aut0 (Swepub:lu)med-plf |
700 | 1 | a Gonzalez, Carlos4 aut |
700 | 1 | a Jakobsen, Marianne Uhre4 aut |
700 | 1 | a Kaaks, Rudolf4 aut |
700 | 1 | a Key, Timothy J.4 aut |
700 | 1 | a Khaw, Kay-Tee4 aut |
700 | 1 | a Kuhn, Tilman4 aut |
700 | 1 | a Mattiello, Amalia4 aut |
700 | 1 | a Nilsson, Peteru Lund University,Lunds universitet,Internmedicin - epidemiologi,Forskargrupper vid Lunds universitet,Internal Medicine - Epidemiology,Lund University Research Groups4 aut0 (Swepub:lu)medf-pni |
700 | 1 | a Overvad, Kim4 aut |
700 | 1 | a Pala, Valeria4 aut |
700 | 1 | a Palli, Domenico4 aut |
700 | 1 | a Quiros, J. Ramon4 aut |
700 | 1 | a Rolandsson, Olovu Umeå universitet,Allmänmedicin4 aut0 (Swepub:umu)olro0005 |
700 | 1 | a Roswall, Nina4 aut |
700 | 1 | a Sacerdote, Carlotta4 aut |
700 | 1 | a Sanchez, Mara-Jose4 aut |
700 | 1 | a Slimani, Nadia4 aut |
700 | 1 | a Spijkerman, Annemieke M. W.4 aut |
700 | 1 | a Tjonneland, Anne4 aut |
700 | 1 | a Tormo, Maria-Jose4 aut |
700 | 1 | a Tumino, Rosario4 aut |
700 | 1 | a van der A, Daphne L.4 aut |
700 | 1 | a van der Schouw, Yvonne T.4 aut |
700 | 1 | a Langenberg, Claudia4 aut |
700 | 1 | a Riboli, Elio4 aut |
700 | 1 | a Wareham, Nicholas J.4 aut |
710 | 2 | a Umeå universitetb Medicin4 org |
773 | 0 | t LANCET DIABETES & ENDOCRINOLOGYg 2:10, s. 810-818q 2:10<810-818x 2213-8587x 2213-8595 |
856 | 4 | u https://umu.diva-portal.org/smash/get/diva2:790584/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 | u https://portal.research.lu.se/files/6549248/8147275x primaryx freey FULLTEXT |
856 | 4 | u http://www.ncbi.nlm.nih.gov/pubmed/25107467?dopt=Abstractx freey FULLTEXT |
856 | 4 | u http://dx.doi.org/10.1016/S2213-8587(14)70146-9x freey FULLTEXT |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-100162 |
856 | 4 8 | u https://doi.org/10.1016/S2213-8587(14)70146-9 |
856 | 4 8 | u https://lup.lub.lu.se/record/4615154 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy